Healthy Skepticism Library item: 17767

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Hopkins Tanne J
GSK is accused of trying to suppress editorial on rosiglitazone
BMJ 2010 May 19; 340:
http://www.bmj.com/cgi/content/extract/340/may19_2/c2654

Abstract:

GlaxoSmithKline faces several new issues over its drug rosiglitazone (Avandia) and possible cardiovascular problems.

The company has had to answer reports that it had asked the European Heart Journal not to publish in print an online editorial that was critical of the drug. It was also reported to have settled lawsuits relating to rosiglitazone and has faced calls for the US Food and Drug Administration to stop an international trial and demands from members of Congress asking why the drug had not been recalled.

The company denied charges, first reported at www.cardiobrief.org, that it had tried to prevent the European Heart Journal from publishing in its print edition an online editorial, “The rise and fall of rosiglitazone,” by Steven Nissen of the Cleveland Clinic (2010;31;773-6, doi:10.1093/eurheartj/ehq016). In 2007 Dr Nissen raised the issue of possible cardiovascular problems with rosiglitazone in a paper in the New England Journal . . .